BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 10811231)

  • 1. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy.
    Brigham KL; Lane KB; Meyrick B; Stecenko AA; Strack S; Cannon DR; Caudill M; Canonico AE
    Hum Gene Ther; 2000 May; 11(7):1023-32. PubMed ID: 10811231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy progress and prospects: alpha-1 antitrypsin.
    Stecenko AA; Brigham KL
    Gene Ther; 2003 Jan; 10(2):95-9. PubMed ID: 12571637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults.
    Brantly ML; Spencer LT; Humphries M; Conlon TJ; Spencer CT; Poirier A; Garlington W; Baker D; Song S; Berns KI; Muzyczka N; Snyder RO; Byrne BJ; Flotte TR
    Hum Gene Ther; 2006 Dec; 17(12):1177-86. PubMed ID: 17115945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release.
    Nita I; Hollander C; Westin U; Janciauskiene SM
    Respir Res; 2005 Jan; 6(1):12. PubMed ID: 15683545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin.
    Sosulski ML; Stiles KM; Frenk EZ; Hart FM; Matsumura Y; De BP; Kaminsky SM; Crystal RG
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of gene therapy for α-1 antitrypsin deficiency.
    Loring HS; Flotte TR
    Expert Opin Biol Ther; 2015 Mar; 15(3):329-36. PubMed ID: 25363251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
    Schmid ST; Koepke J; Dresel M; Hattesohl A; Frenzel E; Perez J; Lomas DA; Miranda E; Greulich T; Noeske S; Wencker M; Teschler H; Vogelmeier C; Janciauskiene S; Koczulla AR
    Int J Chron Obstruct Pulmon Dis; 2012; 7():687-96. PubMed ID: 23055718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results.
    Flotte TR; Trapnell BC; Humphries M; Carey B; Calcedo R; Rouhani F; Campbell-Thompson M; Yachnis AT; Sandhaus RA; McElvaney NG; Mueller C; Messina LM; Wilson JM; Brantly M; Knop DR; Ye GJ; Chulay JD
    Hum Gene Ther; 2011 Oct; 22(10):1239-47. PubMed ID: 21609134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector.
    Conlon TJ; Cossette T; Erger K; Choi YK; Clarke T; Scott-Jorgensen M; Song S; Campbell-Thompson M; Crawford J; Flotte TR
    Mol Ther; 2005 Nov; 12(5):867-75. PubMed ID: 16085464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ).
    Hill AT; Campbell EJ; Bayley DL; Hill SL; Stockley RA
    Am J Respir Crit Care Med; 1999 Dec; 160(6):1968-75. PubMed ID: 10588615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy.
    Zamora NP; Pla RV; Del Rio PG; Margaleff RJ; Frias FR; Ronsano JB
    Ann Pharmacother; 2008 May; 42(5):640-6. PubMed ID: 18413692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.
    Brantly ML; Chulay JD; Wang L; Mueller C; Humphries M; Spencer LT; Rouhani F; Conlon TJ; Calcedo R; Betts MR; Spencer C; Byrne BJ; Wilson JM; Flotte TR
    Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16363-8. PubMed ID: 19706466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency.
    Stockley RA; Bayley DL; Unsal I; Dowson LJ
    Am J Respir Crit Care Med; 2002 Jun; 165(11):1494-8. PubMed ID: 12045122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do native and polymeric alpha1-antitrypsin activate human neutrophils in vitro?
    Persson C; Subramaniyam D; Stevens T; Janciauskiene S
    Chest; 2006 Jun; 129(6):1683-92. PubMed ID: 16778290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased outer arm and core fucose residues on the N-glycans of mutated alpha-1 antitrypsin protein from alpha-1 antitrypsin deficient individuals.
    McCarthy C; Saldova R; O'Brien ME; Bergin DA; Carroll TP; Keenan J; Meleady P; Henry M; Clynes M; Rudd PM; Reeves EP; McElvaney NG
    J Proteome Res; 2014 Feb; 13(2):596-605. PubMed ID: 24328305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency.
    Borel F; Tang Q; Gernoux G; Greer C; Wang Z; Barzel A; Kay MA; Shultz LD; Greiner DL; Flotte TR; Brehm MA; Mueller C
    Mol Ther; 2017 Nov; 25(11):2477-2489. PubMed ID: 29032169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Intravenous Administration of an AAV8 Vector Coding for an Oxidation-Resistant Human α1-Antitrypsin for the Treatment of α1-Antitrypsin Deficiency.
    Rosenberg JB; De BP; Greco A; Gorman N; Kooner V; Chen A; Yost-Bido M; Munoz-Zuluaga C; Kaminsky SM; Rostami M; Monette S; Crystal RG; Sondhi D
    Hum Gene Ther; 2023 Feb; 34(3-4):139-149. PubMed ID: 36606685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenging identification of a novel PiISF and the rare PiMmaltonZ α1-antitrypsin deficiency variants in two patients.
    Suh-Lailam BB; Procter M; Krautscheid P; Haas J; Kumar S; Mao R; Grenache DG
    Am J Clin Pathol; 2014 May; 141(5):742-6. PubMed ID: 24713750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice.
    Lu Y; Tang M; Wasserfall C; Kou Z; Campbell-Thompson M; Gardemann T; Crawford J; Atkinson M; Song S
    Hum Gene Ther; 2006 Jun; 17(6):625-34. PubMed ID: 16776571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of gene expression and increase in alpha1-antitrypsin (alpha1-AT) secretion after homologous recombination in alpha1-AT-deficient monocytes.
    McNab GL; Ahmad A; Mistry D; Stockley RA
    Hum Gene Ther; 2007 Nov; 18(11):1171-7. PubMed ID: 17937578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.